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The Optimal Selection of Radiotherapy Treatment for Hepatocellular 
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Department of Radiation Oncology, Yonsei Liver Cancer Clinic, Yonsei University College of Medicine, Seoul, Korea
The majority of patients who present with hepatocellular 
carcinoma (HCC) are already at an advanced stage, and 
the tumors are unresectable. Radiotherapy (RT) technology 
can safely provide focused high-dose irradiation to these 
patients. A wide spectrum of RT technologiesis currently 
available, including internal RT consisting of Yttrium-90 
(
90Y), Iodine-131 (
131I) anti-ferritin antibody and Homium-199 
(
199Ho) and external RT, such as three-dimensional conformal 
RT, intensity-modulated RT, helical tomotherapy, stereotactic 
body RT, and image-guided RT. However, it may be difﬁ  cult for 
physicians to understand all of the available options and to 
select the optimal RT treatment. Physicians frequently query 
radiation oncologists on the practical indications of RT for 
managing patients with HCC. According to the Korean Liver 
Cancer Study Group practice guidelines, RT is considered 
appropriate for unresectable, locally advanced HCC without 
extrahepatic metastasis, a Child-Pugh class A or B, and tu-
mors that occupy less than two-thirds of the liver with level II 
evidence. In this review, we discuss the application of various 
RT modalities based on disease status and the detailed indi-
cations for RT according to the Barcelona Clinic Liver Cancer 
staging system. (Gut Liver 2012;6:139-148)
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INTRODUCTION
Hepatocellular carcinoma (HCC) represents a critical issue in 
global health. Cancer statistics list this disease as the third most 
common cause of cancer-related deaths worldwide.
1 Accord-
ing to guidelines of the American Association for the Study 
of Liver Diseases (AASLD), potentially curative therapies can 
treat the very early and early stages of the disease. However, 
less than 30% of HCC patients are detected with the disease in 
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those stages.
2 Another 20% of patients with terminal stage HCC 
receive recommendations for the best supportive treatment. 
Since HCC is unresectable in the majority of patients at the time 
of the first diagnosis, patients are often directed to nonsurgical 
treatments. Physicians have long overlooked radiotherapy (RT) 
for HCC as radiation might induce fatal hepatic toxicity at doses 
lower than the therapeutic doses.
3,4 However, such limitation 
has been overcome by recent developments in RT technology 
involving precise delivery of focused high-dose on partial vol-
ume of the liver.
5-10 According to the Korean Liver Cancer Study 
Group (KLCSG) practice guidelines, RT is considered appropriate 
for unresectable, locally advanced HCC without extrahepatic 
metastasis, Child-Pugh class A or B, and tumors occupying less 
than two-thirds of the liver. The evidence level is upgraded from 
level III in the 2003 version to level II in the 2009 KLCSG guide-
lines.
11,12 
In this review, we will first describe the application of vari-
ous RT modalities by disease status. Then, we will discuss the 
indications for RT according to the HCC stage. Unlike other 
cancers, many staging systems are used for HCC, including the 
Barcelona Clinic Liver Cancer (BCLC) staging,
13 tumor-node-
metastasis (TNM),
14 Okuda,
15 Cancer of the Liver Italian Program 
(CLIP),
16 and Japan Integrated Staging (JIS) scoring system.
17 In 
our previous study comparing staging systems, The TNM stag-
ing system appears to be the best in predicting the prognosis for 
HCC patients treated with RT.
18 However, our discussion will be 
based on the BCLC staging system as it currently serves as the 
basis for treatment decisions.
APPLICATION OF VARIOUS RT MODALITIES
There are several strategies that may be used to deliver 
radiation to HCC. Currently, a variety of RT modes are avail-
able, which range from internal RT such as yttrium-90 (
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external RT such as three-dimensional conformal RT (3D-CRT) 
and intensity modulated RT (IMRT). While some techniques are 
machine-dependent and involves protons, a modality which 
combines IMRT and image guided RT (IGRT) has been emerged 
for higher precision. However, modification of the fractionation 
scheme such as hypofractionated RT and stereotactic body RT 
(SBRT) may also be possible within a typical RT machine. 3D-
CRT is the most commonly used platform of RT technology (Fig. 
1).
19,20
INTERNAL RT
RT could be classified to internal and external RT. Internal RT 
using regional radionuclide therapeutic options are increasingly 
available for HCC patients and appears promising. Radiola-
beled antibodies used by Pressman for radioimmunodetection 
of tumors showed that iodination with Iodine-131 (
131I) did not 
destroy antibody activity and has resulted in tumor remissions 
in diverse cancers.
21,22 Order et al.
23 evaluated the efficacy of 
131I 
anti-ferritin antibody and systemic CTx in treating HCC. Early 
attempts using monoclonal 
131I anti-ferritin antibody were not 
successful, as outcomes were no better than with chemothera-
py.
24 Tumor-specificity and tumor-retention remain challenges 
in radioimmunotherapy. 
90Y, a pure β-emitter, decays to stable 
zirconiumi-90 with a physical half-life of 2.7 days. Radioem-
bolization with 
90Y represents a novel form of liver-directed 
brachytherapy.
25,26 This approachcanbe applied to unresectable 
HCC. It also may be used for the treatment of unresectable HCC 
in patients with branch/partial portal vein thrombosis (PVT). A 
preliminary safety analysis in 15 patients with unresectable HCC 
and PVT without cavernous transformation has been reported.
27 
Kulik et al.
28 evaluated phase II study about the safety and clini-
cal benefit of radioembolization in a larger cohort of patients 
with unresectable HCC complicated by PVT. Homium-199 
(
199Ho), mostly beta and a little gamma emission with a half-
life of 26.8 hours, has also been tried in chitosan complex form 
either intratumorally or transarterial approach. Percutaneous 
intratumoral Holmium injection showed excellent tumor control 
in HCCs with complete response rate 77.5% for tumors smaller 
than 3 cm and 91.7% for smaller than 2 cm.
29 Intraarterial ap-
proach also showed promising result in tumors smaller than 5 
cm.
29,30
EXTERNAL RT
1. 3D-CRT
3D-CRT which involves shaping of the profile of each radia-
tion beam to fit the profile of the target from the beam’s eye 
view (BEV), uses a multi-leaf collimator (MLC) and a various 
number of beams. For the 3D-CRT, computed tomography (CT) 
scan images should be taken in the treatment position, and 
clinical target volume and target volume for RT needs to be 
delineated. The target is localized by establishing the positions 
of several optical markers relative to the target volume in a CT 
simulator. 
Several factors should be considered when treating liver 
tumors with RT. First, the proximity of the liver to other radio-
sensitive organs should be considered, such as the duodenum, 
colon, small intestines, and kidneys according to Couinaud’s 
segmentation. Park et al.
10 reported that 26 of 47 patients (55.3%) 
who were irradiated on the right lobe only developed acute 
morbidity such as nausea and vomiting, and 11 of 12 patients 
(91.7%) who were irradiated on the left lobe developed acute 
morbidity. In our previous report on 50 HCC patients treated 
with 3D-CRT combined with transcatheter arterial chemoembo-
lization (TACE), 7 patients developed gastro-duodenal side ef-
fects, 6 patients developed radiation-induced liver disease (RILD). 
One of them received the treatment for a tumor located in seg-
ment 5 of the liver and then developed subacute colitis.
19 
The second factor involves the liver and tumor movement 
along with respiration. When applying 3D-CRT without image-
guided technology, cephalo-caudal movement of the target 
organ should be considered. Reducing respiratory motion can 
be attempted by abdominal compression which can decrease the 
target margins.
2. IMRT 
IMRT, an advanced 3D-CRT, uses non-uniform beam in-
tensity patterns with computer-aided optimization to achieve 
superior dose distribution.
31 As it can change the intensity of 
individual rays within each beam, IMRT allows greater control 
of dose distribution and improves the ability to cover the treat-
ment volume to concave tumor shapes. Cheng et al.
32 compared 
Fig. 1. The application of various radiotherapy (RT) modalities. The 
type of RT should be determined according to the Barcelona Clinic 
Liver Cancer (BCLC) stage and liver function. The use of image-
guided technology for the precise delivery of RT, such as intensity-
modulated radiotherapy (IMRT) and stereotactic body radiotherapy 
(SBRT), is essential.
3D-CRT, three-dimensional conformal radiotherapy; IGRT, image 
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dose-volume data between 3D-CRT and IMRT for patients with 
HCC. They found that IMRT achieved a large dose reduction in 
the spinal cord and spared the kidneys and stomach. IMRT ex-
erted diverse dosimetric effects on the liver, significantly reduc-
ing the normal tissue complication probability (p=0.009), but 
significantly increasing the mean dose compared with 3D-CRT 
(p=0.009). 
Helical tomotherapy (HT), another kind of fusion technology 
that combines IMRT and IGRT,
33,34 provides better dose coverage 
for tumors, thanks to its 360° beam arrangement and helical de-
livery of radiation. Some studies have reported improved spar-
ing of adjacent normal organs when using HT in various tu-
mors, and HT offers increased dose conformity to the tumor and 
reduces doses delivered to sensitive structures.
35,36 For liver tu-
mors, HT could increase the dose conformity to the tumor with 
PVT and reduce the doses delivered to the non-cancerous parts 
of the liver. Fig. 2 is a case of 57-year-old man diagnosed HCC 
with PVT and an underlying chronic B viral hepatitis. He was 
treated with concurrent intra-arterial chemotherapy and HT (50 
Gy/20 fractions) and received intra-arterial chemotherapy for 1 
year. The main mass and PTV disappeared and he was followed 
with no evidence of disease until 30 months after completion 
of concurrent chemoradiotherapy (CCRT). Although he had re-
curred on the intrahepatic parenchyma after 30 months, he has 
been well with the disease after two times of TACE and radiofre-
quency ablation (RFA) once. In a dose-distribution comparison 
study of 3D-CRT, linac-based IMRT, and HT, we found that HT 
decreased high-dose radiation to certain critical structures like 
the stomach, whereas the mean hepatic dose increased.
37
3. SBRT 
SBRT offers a technique designed to very precisely deliver ra-
diation to tumors anywhere in the body. The word “stereotactic” 
pertains to the precise positioning of a tumor in relationship to 
the body. The technology used in SBRT allows the delivery of 
external beam radiation with pinpoint accuracy. Such advance-
ment in the accuracy of radiation treatments allows the delivery 
of higher doses of radiation, thus potentially improving the like-
lihood of killing cancer cells of a tumor. Another benefit to im-
proved accuracy means that treatments require less time. Typi-
cally, SBRT consists of three to five treatments which are carried 
out over one to two weeks. The precision associated with SBRT 
simultaneously helps reduce the dose of radiation to normal 
tissue around a tumor, thus helping to reduce side effects for 
patients. Many studies, including the present one, have shown a 
dose-response relationship between conventional RT doses and 
responses in HCC.
38,39 Seo et al.
40 reported on the toxicity and ef-
ficacy of SBRT for the treatment of localized HCC in the absence 
of another standard treatment option. They administered SBRT 
dosages (33 to 57 Gy in three or four fractions) according to 
tumor volumes (median, 40.5 mL). They reported 2-year overall 
survival as 61.4%, local progression-free survival rates 66.4%, 
and a local response rate 63% at 3 months after SBRT. They 
found a high radiation dose independently related to survival. 
Furthermore, they reported a decline in liver function in six pa-
tients (16%) and Grade 3 musculoskeletal toxicity in one patient 
(2.7%). They suggested SBRT technique as a salvage treatment. 
Louis et al.
41 evaluated 25 HCC patients who were not eligible 
for other modalities. A total dose of 45 Gy in three fractions of 
Fig. 2. The case of a 51-year-old man diagnosed with a huge left hepatocellular carcinoma (15 cm) and portal vein thrombosis. He was treated 
with concurrent intra-arterial chemoradiotherapy and received 6 cycles of intra-arterial chemotherapy. The patient underwent a left lobectomy 15 
months after treatment and showed complete pathologic remission. (A) The computed tomography images at the initial presentation, (B) after 1 
month, and (C) showing a partial response after 15 months.142  Gut and Liver, Vol. 6, No. 2, April 2012
15 Gy each was prescribed to the 80% isodose line (95% of the 
PTV received 45 Gy) and delivered to the target volume over 10 
to 12 days. The actuarial 1- and 2-year local control rate was 
95%. Overall 1- and 2-year actuarial survival rates were 79% 
and 52%, respectively.
41 Several prospective studies have been 
conducted. Tse et al.
42 reported outcomes of a phase I study 
of individualized SBRT for unresectable HCC and intrahepatic 
cholangiocarcinoma (IHC). The patients were treated with six-
fraction SBRT during 2 weeks. Median survival of HCC and IHC 
patients was 11.7 months and 15.0 months, respectively.
42 A 
Phase I dose escalation trial of SBRT for primary HCC at Indiana 
University showed one and 2-year overall survivals of 75% and 
60%, respectively.
43
4. IGRT
IGRT indicates the process of frequent two- and three-
dimensional imaging during a course of radiation treatment to 
check physical uncertainties related to setup variation, organ 
movement, and tissue deformation. Target localization systems 
control such uncertainties, and the tools of images for IGRT in-
clude kilovoltage radiograph fluoroscopy, conebeam CT (CBCT), 
and megavoltage CT (MVCT). It is essential to use IGRT for pre-
cise RT such as IMRT and SBRT. SBRT entails the stereotactic 
delivery of ablative doses of radiation to a target/tumor volume, 
and it typically uses very tight margins to minimizes collateral 
damage to critical structures and organs. Therefore, a robust im-
mobilization device is crucial to ensure a reproducibly accurate 
set-up, allowing a tighter margin expansion for planning treat-
ment volume. Furthermore, tumors in the liver are subject to 
respiratory motion, which must be controlled and accounted for 
during CT simulation, treatment planning, and treatment deliv-
ery.
44,45
PARTICLE BEAM THERAPY
1. Proton therapy
Proton therapy, a type of positively charged particle therapy, 
has a unique dose distribution that makes it suitable for treat-
ment of deep tumors surrounded by normal structures, thanks to 
the unique physical characteristics of the depth-dose curve. Pho-
ton depth-dose curves show an exponentially decreasing energy 
deposition with increasing depth in tissue after a short build-up. 
By contrast, protons particles deposit their radiation energy as 
they slow down, and show a dose peak (Bragg peak) at a well-
defined depth in tissue. Consequently, this results in no exit 
dose. This has advantages such as a lower dose in the entrance 
region than the dose delivered to the tumor regions even when 
using a single treatment angle. The second advantage, owing to 
the finite range and sharp distal fall-off, a radiation dose can be 
directed to a critical structure. Several authors reviewed clinical 
outcomes of HCC patients treated with proton therapy.
46-48 The 
literature includes two prospective phase II studies on proton 
therapy for HCC. Bush et al.
49 performed a study with 34 pa-
tients with locally unresectable HCC. The total dose included 
63 cobalt Gy equivalents, administered in 15 fractions over 3 
weeks. Three patients experienced duodenal or colonic bleeding. 
A 2-year actuarial local control rate of the treatment was 75%, 
and an overall survival rate was 55%.
49 Kawashima et al.
50 per-
fromed a phase II study of proton therapy for HCC patients, and 
reported a 2-year actuarial local progression-free rate of 96% 
and a 2-year actuarial overall survival rate of 66%. However, 
there are limited data regarding the efficacy of this treatment on 
HCC. 
RT ACCORDING TO BCLC STAGE
The BCLC staging system, which is endorsed by the AASLD 
and European Association of Study of Liver (EASL), provides 
both tumor staging and treatment guidelines. For early stage 
HCCs, for example, resection, liver transplantation, or percu-
taneous ablation is recommended. Patients in intermediate or 
advanced stages are considered for palliation. 
1. BCLC stage 0 or A
For small, solitary HCC lesions with BCLC stage 0 or A, the 
first treatment choice is local ablation such as RFA or percuta-
neous ethanol injection therapy (PEIT). However, the areas right 
below the hepatic dome and adjacent to the main portal vein 
are particularly susceptible to complications with other local 
ablation therapies. When these options are limited by techni-
cal difficulties in patients who are inoperable or refuse surgery, 
TACE has been widely used in Asian countries.
51-54 Recently, 
there are several reports that SBRT also can be an appropriate 
alternative or adjuvant (Fig. 1).
42,55,56 Andolino et al.
56 evalu-
ated the safety and efficacy of SBRT for the treatment of pri-
mary HCC. Sixty patients with liver-confined HCC were treated 
with SBRT and the median follow-up time was 27 months. 
The 2-year local control, progression-free survival, and overall 
survival were 90%, 48%, and 67%, respectively, with median 
time to progression of 47.8 months. They showed SBRT is a 
safe, effective, noninvasive option for patients with HCC ≤6 cm. 
Authors also suggested that SBRT should be considered when 
bridging to transplant or as definitive therapy for those ineli-
gible for transplant. Takeda et al.
57 recommended combination 
therapy of TACE plus SBRT for solitary tumors distant from the 
gastrointestinal tract and kidneys with a tumor volume <100 
cm
3. Large tumors or tumors close to adjacent radiosensitive or-
gans should be treated with conventional or precise RT such as 
IMRT. Table 1 summarized the clinical results of RT according 
to BCLC stages. 
2. BCLC stage B
For BCLC B, TACE is recommended. The efficacy of TACE has 
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intermediate stage.
52,58,59 However, the effect of TACE limited by 
vascular shunting, recanalization around the tumor capsule, as 
well as development of multiple feeding vessels.
60,61 TACE was 
repeatedly performed to overcome the limitation. However, it 
frequently results in outgrowth of HCCs refractory to TACE. In-
stead, RT can provide a complementary effect. 
The effect of RT in addition to TACE has been investigated 
by comparing TACE followed by RT vs TACE only or repeated 
TACE. The result showed a significant improvement in overall 
survival with TACE combined with RT. Shim et al.
9 used RT 
following incomplete responses to TACE and reported response 
rates greater than 60%. Of 73 patients with HCC with an incom-
plete response to TACE, 38 patients received RT and 35 received 
repeated TACE alone. Patients treated with RT showed a sig-
Fig. 3. Radiotherapy according to 
the Barcelona Clinic Liver Cancer 
stage. Inoperable, not feasible for 
curative treatment, or locally recur-
ring hepatocellular carcinoma (HCC) 
can be managed using radiotherapy. 
Solitary tumors distant from the gas-
trointestinal tract and kidneys with a 
tumor volume <100 cm
3 are eligible
for stereotactic body radiotherapy 
(SBRT).
PST, performance status; PEI, per-
cutaneous ethanol injection; RF, 
radiofrequency; TACE, transcatheter 
arterial embolization; CCRT, concur-
rent chemoradiotherapy; iA CTx, 
intraarterial chemotherapy.
Table 1. A Summary of the Definition of BCLC Stages and the Results of Radiotherapy
BCLC stage* Okuda stage Definition Liver function/PST Applications of radiation Median survival
Very early stage (0) 0 Single <2 cm 
Carcinoma
in situ
Child A/0 SBRT alone or TACE+SBRT  44.4
56
Early stage (A) 1-2 Single to 3 nodules, <3 cm Child A-B/0 TACE+RT 16-20
39,65
Intermediate stage (B) 1-2 Multinodular Child A-B/0 TACE+RT
Advanced stage (C) 1-2 Portal invasion, N1, M1 Child A-B/1-2 CCRT→iA CTx 15.2-16.7
69,76
Terminal stage (D) 3 Disseminated Child C/>2 Palliative RT 2-5.1
80-82
BCLC, Barcelona Clinic Liver Cancer; PST, performance status; SBRT, stereotactic body radiotherapy; TACE, transcatheter arterial embolization; 
RT, radiotherapy; CCRT, concurrent chemoradiotherapy; iA CTx, intra-arterial chemotherapy. 144  Gut and Liver, Vol. 6, No. 2, April 2012
nificant improvement in 2-year survival rate (37% vs 14% for 
TACE plus RT vs TACE alone, p=0.001). The survival difference 
was greater in patients with large tumors; 2-year survival rates 
in TACE plus RT versus TACE alone were 63% vs 42% in 5 to 7 
cm tumors, 50% vs 0% in 8 to 10 cm tumors, and 17% vs 0% in 
tumors larger than 10 cm, respectively. Other investigators have 
reported a similar range of response rates with TACE followed 
by RT.
62-65 
For multiple nodular lesions, repeated TACE is a common 
treatment option. However, with an increasing number of TACE 
procedures, incomplete TACE triggers tumor hypoxia, subse-
quently resulting in HCC either refractory to the treatment or 
facilitating intra- or extra hepatic metastasis. For focal HCC, 
delivery of concurrent RT can improve local control. In patients 
presenting with a large tumor and multiple small nodules, TACE 
can effectively control the small lesions, while RT could be used 
to target the largest lesion. Koom et al.
66 questioned the use-
fulness of local RT in multifocal HCC. In their report, patients 
with viable intrahepatic tumors not targeted with RT had worse 
survival that those treated with targeted RT; in patients with 
intrahepatic tumors treated with TACE but without targeted RT, 
outcomes were comparable to patients with a single tumor. 
3. BCLC stage C
BCLC stage C represents a variety of disease spectrum, in-
cluding metastasis, portal vein invasion, and performance 0 to 
2. In this stage, sorafenib is suggested as the standard of care. 
Sorafenib is an orally-active inhibitor of multiple tyrosine ki-
nases including vascular endothelial growth factor receptor and 
Raf/mitogen-activated protein kinase. The Sorafenib Hepatocel-
lular Carcinoma Assessment Randomized Protocol (SHARP) and 
Asia-Pacific SHARP trial found that treatment of HCC patients 
with sorafenib resulted in improved overall survival. However, 
the gain in survival is modest and new treatment strategies are 
still needed.
67,68 In a radiation oncologist’s view, BCLC stage C 
with portal vein invasion or lymph node involvement could be 
treated with RT when the tumor does not respond to sorafenib 
or chemoembolization or shows progression (Fig. 3).
69 The 
KLCSG practice guidelines suggest RT for locally advanced 
tumors with evidence of level II. Locally advanced HCC which 
is considered not amenable to surgical resection or immediate 
liver transplantation, should be locally advanced as defined by 
the BCLC intermediate stage (B) or the BCLC  advanced stage 
(C) without extrahepatic spread, except regional lymph node 
involvement.
70
For patients with PVT, several studies reported promising re-
sponse level of the 3D-CRT.
71,72 Objective response ranged from 
37.5% to 50%.
73,74 Kim et al.
75 reported that RT induced 45.8% 
objective response with a median survival time of 10.7 months 
in responders and 5.3 months in non-responders for PVT in 
patients with HCC. They found a dose-response relationship 
between the RT dose and PVT response. RT for advanced HCC 
may be used in combination with systemic agents. Han et al.
76 
reported localized CCRT followed by hepatic arterial infusion 
chemotherapy (HAIC) in patients with locally advanced HCC, 
PVT, and good reserve liver function. They observed an objec-
tive response in 18 of 40 patients (45%) and an actuarial 3-year 
overall survival rate of 24.1%. The same group updated the 
treatment outcomes in 101 patients, leading to a median sur-
vival of 16.7 months. In selected patients, CCRT can convert un-
resectable HCCs to resectable ones. In our institute, among 156 
unresectable HCC patients who received CCRT, 14 patients (9%) 
underwent hepatic resection (Fig. 4). RT directed to the PVT area 
has been reported an objective response rate of 37.5% to 71.4%, 
with a median survival time of 6.7 to 10.7 months.
71,73,74,77 Lin et 
al.
77 analyzed the recanalization rate of PVT and treatment tox-
icity after SBRT or 3D-CRT in 14 patients in a prospective study 
with a total of 43 patients. The crude response rate was 79%, 
and the median survival time was 6.0 for the SRT group and 6.7 
months for 3D-CRT group. 
To determine the scope of the radiation field, our institute 
recommends that the field should cover the primary gross tu-
mor, including PVT. Since this group of patients had already 
advanced disease, a high risk for failure can easily be expected. 
Fig. 4. The case of a 57-year-old man diagnosed with hepatocellular carcinoma and portal vein thrombosis. He was treated with concurrent intra-
arterial chemotherapy and helical tomotherapy (HT) (50 Gy/20 fractions) and received intra-arterial chemotherapy for 1 year. (A) Axial, coronal, 
and sagittal isodose distribution of HT, (B) Positron emission tomography-computed tomography (PET-CT) images before HT, (C) PET-CT images 2 
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In our retrospective study of 161 HCC patients treated by CCRT 
through hepatic arterial infusion, several factors were identified 
for predicting treatment failure. The pretreatment AFP ≥500 ng/
mL was a significant factor influencing intrahepatic-outfield 
and extrahepatic failure, and <55 years age at diagnosis in-
creased the incidence of extrahepatic failure. The previous treat-
ment before CCRT was associated with infield failure.
78
4. BCLC stage D
Patients with HCC in terminal stage D need full symptomatic 
palliation for local disease or distant metastasis. Palliative RT 
is indicated for metastasis to lymph node, bone, brain, or other 
sites. For lymph node metastases from HCC, Yoon et al.
79 sug-
gested that RT doses of 45 Gy or higher to achieve a significant 
response. Seong et al.
80 reported an overall response rate of 
79.5% in 39 patients. The response rate was 87.5% in patients 
receiving ≥40 Gy10 (biologically effective dose, alpha/beta=10) 
and 42.9% in patients receiving <40 Gy10 (p=0.02). Responders 
had a median survival time of 10 months, and non-responders 
had a response rate of 6 months (p=0.01). For bone metastasis, 
RT showed complete pain relief in 50% of patients and partial 
pain relief in 80% to 90%. Nakamura et al.
81 evaluated the ther-
apeutic effects of RT on spinal metastases from HCC. They re-
ported the ambulatory rate of 85% after 3 months and 63% af-
ter 6 months, and the local progression-free rate was 53% after 
3 months and 47% after 6 months. Brain metastasis from HCC 
is extremely rare. Choi et al.
82 carried out a retrospective review 
of 62 patients. Seventeen of them were treated with whole-brain 
radiation therapy (WBRT) alone, 10 others with gamma knife 
surgery alone, 6 patients surgical resection only, and 5 patients 
with surgical resection followed by WBRT. The median survival 
time was 6.8 weeks (95% confidence interval, 3.8 to 9.8 weeks) 
since diagnosis of brain metastasis. Treatment modality, number 
of brain lesions, and Child-Pugh classification represented sig-
nificant prognostic factors for survival. 
SUMMARY AND CONCLUSION
As discussed in the review, RT can be a useful therapy for 
tumors in various stages according to the BCLC system. It can 
serve as a nonsurgical curative therapy for stage 0 or A. It also 
can be combined with other treatments such as TACE for stage 
B. For stage C, RT in combination treatment can prolong the 
survival time in selected patients who present locally advanced 
HCC associated with portal vein invasion but not distant metas-
tasis. For patients with stage D tumors, RT can provide effective 
palliation. 
A variety of new RT machines are currently available, which 
could make it difficult for physicians when determining their 
choice of treatment. Although 3D-CRT has been the standard 
mode, it is highly recommended to use a precision RT technolo-
gy involving intensity modulation as well as image-guided one. 
In particular, IGRT is an essential component of the advanced 
RT process. 
However, the superiority of these sophisticated technologies 
has not been proven in terms of survival benefits yet.
48,83 Further 
clinical study in the radiation treatment of HCC is necessary to 
confirm its role in multidisciplinary management of HCC.
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